$ACMR

Wang David H (See Remarks) sold 140,000 shares of ACM Research, Inc. (ACMR) at an average of $75.93 ($73.80–$78.57, $10.63M total) across 9 trades over 2026-09-08 to 2026-09-09 under a Rule 10b5-1 trading plan.

Snowflake (SNOW) rose 19.9% after strong earnings and raised guidance. Campbell's (CPB) fell 10.8% on weak forecasts and dividend cut. Ciena (CIEN) dropped 9.9% despite earnings beat due to margin outlook. ACM Research (ACMR) saw heavy call activity. Options volume surged for all four stocks.

Morgan Stanley identifies SpaceX, ACM Research, Amkor Technology, Alibaba, and KLA as key beneficiaries of the AI sovereignty trend. The bank assigns price targets with upside potential ranging from 21% to 105%, highlighting the strategic importance of AI infrastructure for national security and economic competitiveness.

ACM Research (Shanghai) reported a 105% year-over-year increase in new orders for the first half of 2026, with growth across electroplating, cleaning, and advanced packaging equipment. The company expects gross margins to remain between 42% and 48%. Significant orders include panel-level electroplating systems for delivery in 2026 and 2027. ACM Shanghai also highlighted rapid growth in mature-node semiconductor manufacturing and AI-related equipment demand.

China's tech sector shows resilience despite tariffs and geopolitical tensions. Key companies like ACM Research (ACMR), GDS Holdings (GDS), Kingsoft Cloud (KC), and Taiwan Semiconductor (TSM) are highlighted as investment opportunities. TSM reported strong Q3 2026 guidance, with revenues projected at $44.6-$45.8 billion. ACMR raised full-year 2026 revenue guidance to $1.125-$1.175 billion. GDS increased revenue and EBITDA guidance, driven by AI demand. KC saw AI cloud revenues grow 82% year over

ACM Research (ACMR) has seen rising earnings estimates, with current-quarter EPS expected at $0.51 (+41.7% YOY) and full-year EPS at $2.05 (+27.3% YOY). The Zacks Consensus Estimate increased 86.36% over 30 days. The company has a Zacks Rank #1 (Strong Buy), indicating potential for further stock price appreciation.

Analysts initiated coverage on several companies: Needham rated Evommune (EVMN) Buy with a $28 target, Daiwa rated ACM Research (ACMR) Buy with a $136 target, Wolfe Research rated Harmony Biosciences (HRMY) Outperform with a $60 target, RBC rated Atlassian (TEAM) Outperform with a $215 target, and RBC rated JFrog (FROG) Outperform with a $118 target.

On Friday, notable insider trading activity was reported for several US-listed companies. Global Water Resources (GWRS) directors bought shares, with Jonathan L. Levine acquiring 651,618 shares at $8.85 each. AEON Biopharma (AEON) director Timothy P. Lynch purchased 1.15M shares at $0.2117 each. Cloudflare (NET) president Michelle Zatlyn sold $28.3M worth of shares. Illumina (ILMN) director Keith A. Meister sold $145.56M in shares. InvestingPro analysis provided valuation insights for these comp

ACM Research CFO Mark McKechnie sold $4.26M in shares and acquired $935,828 worth via options. Shares sold at $76.34-$77.89, currently at $79.41. ACMR reported Q2 earnings of $0.61 per share on $292.9M revenue, beating estimates. The company raised its full-year revenue outlook. Analysts note high volatility and potential overvaluation.

McKechnie Mark (See Remarks) sold 55,199 shares of ACM Research, Inc. (ACMR) at an average of $77.27 ($76.34–$77.89, $4.26M total) across 3 trades on 2026-08-20 under a Rule 10b5-1 trading plan.